How might we successfully treat diabetes patients who become seriously ill and hospitalised sufffering from Coronavirus and requiring ventillator breathing assistance?
Coronavirus, Covid-19 is the most feared pandemic ever experienced on a global scale with dramatic morbidity and is challenging to treat and overcome. Media reports suggest that 25% of patients who die from Coronavirus are elderly and have an underlying health condition, often diabetes.
Could inhaled therapy drug treatment delivered to Critical Care Patients with the Multisonic®Infracontrol Nebuliser lead to improved recovery and reduced morbidity?
